semaglutide compounding ending ๐จ FDA Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale of GLP-1 medications like and tirzepatide, signaling a major shift in how these FDA alerts health care providers,
Description
Dispensing of glucagon-like peptide-1 receptor agonists to adolescents and young adults, 20202023

We need someone to actually do that research first,which probably wont happen until the Phase 3 Trials for Retatrutide are over, but even that isnt a fair comparison because of the GCGR activity

The 60-day initiation (first-time dispense) rates were higher for ADMs compared to AOMs

Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study
